Sophia Genetics
Swiss-founded data-driven medicine company providing genomic, radiomic, and multimodal analysis software for healthcare and life-science organizations.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Sophia Genetics SA is a Swiss-founded health-technology and biotechnology company that develops software for data-driven medicine. Its products are designed to help hospitals, clinical laboratories, biopharmaceutical companies, and research institutions interpret complex biological and medical data. The company is best known for the SOPHiA DDM Platform, an analytical environment that applies computational methods and artificial intelligence to genomic diagnostics, including data generated by next-generation sequencing. The company was established in 2011 by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz as a start-up associated with the École Polytechnique Fédérale de Lausanne. It initially focused on helping hospitals and regulated healthcare laboratories process and interpret large genomic datasets. As its work developed, the company placed greater emphasis on the accuracy and clinical interpretation of genomic information rather than simply on data storage and management. Sophia Genetics introduced the SOPHiA DDM Platform in 2014. The platform was developed to support the analysis of genomic data from biological samples, including blood, urine, cerebrospinal fluid, and other liquid specimens. Its stated areas of use include oncology, hereditary cancer, metabolic disease, pediatrics, cardiology, and rare-disease research. The platform can support interpretation of sequencing results and, through later extensions, radiomic and other multimodal data. This positions Sophia Genetics between laboratory diagnostics, clinical decision support, and specialized bioinformatics rather than as a conventional consumer genetic-testing brand. The company expanded internationally during the late 2010s. In 2018, it established a research and development center in France, acquired Interactive Biosoftware, and opened a United States headquarters in Boston. The same period also saw the acquisition of Nénuphar technology, described as using patient data and algorithms to help predict tumor growth. These moves broadened the company’s capabilities in molecular biology software, clinical analytics, and predictive oncology. Sophia Genetics has pursued partnerships across the sequencing and healthcare ecosystem. Its relationships have included Illumina, Integrated DNA Technologies, Paragon Genomics, MGI, Hitachi, GE HealthCare, Memorial Sloan Kettering Cancer Center, QIAGEN, AstraZeneca, NVIDIA, and Microsoft. The collaborations have covered sequencing adoption, assay development, variant detection, clinical analytics, predictive tumor analysis, and whole-genome sequencing applications. The company also released a SARS-CoV-2 disease-evolution analysis solution in 2020 and later worked on methods for detecting extrachromosomal DNA with Boundless Bio. Sophia Genetics completed an initial public offering in July 2021 with J.P. Morgan, Morgan Stanley, and Credit Suisse among the underwriting banks. Its subsequent strategy has continued to center on expanding access to data-driven genomic interpretation and connecting molecular, imaging, and clinical information. The company’s business is primarily enterprise and institution-facing: it provides software and analytical infrastructure to professional users rather than selling direct-to-consumer ancestry or wellness tests. The available reference material does not establish a current chief executive, current share ticker, official website URL, or detailed financial figures.
History
Sophia Genetics was founded in 2011 by Jurgi Camblong, Pierre Hutter, and Lars Steinmetz as a start-up connected with the École Polytechnique Fédérale de Lausanne in Switzerland. Its earliest work addressed a practical problem faced by hospitals and federally regulated healthcare laboratories: how to process, store, and interpret the growing volume of genomic information produced by modern sequencing technologies. The company’s initial orientation was therefore institutional and clinical rather than consumer-facing. In 2014, Sophia Genetics introduced the SOPHiA DDM Platform, its principal data-driven medicine software environment. The platform was designed to improve genomic diagnostics by applying advanced analytics and artificial-intelligence techniques to next-generation sequencing data. It supported analysis of samples such as blood, urine, cerebrospinal fluid, and other liquid specimens, with applications in oncology, hereditary cancers, metabolic disorders, pediatrics, cardiology, and rare-disease research. The company’s development focus evolved from basic genomic data handling toward data quality, variant interpretation, and clinically useful outputs. Sophia Genetics expanded its technology and geographic footprint in 2018. It established its first research and development center in France, acquired Interactive Biosoftware, a France-based molecular biology and genetic-analytics software company, and opened a United States headquarters in Boston, Massachusetts. It also acquired or incorporated Nénuphar technology, which used patient information and algorithms to help predict tumor growth. These developments strengthened the company’s capabilities in molecular analysis and predictive oncology while giving it a larger presence in European and American healthcare markets. The company built an ecosystem of sequencing, diagnostic, healthcare, and pharmaceutical relationships. In 2016, it entered a co-marketing arrangement with Illumina to encourage adoption of next-generation DNA sequencing. In 2019, it worked with Integrated DNA Technologies and Paragon Genomics on COVID-19 test-kit activities. During 2021, MGI users gained access to the SOPHiA DDM Platform, while Sophia Genetics also announced collaborations with Hitachi and GE HealthCare. The GE HealthCare work concerned analytics capable of relating treatment regimens to a patient’s genomic signature, cancer type, and longitudinal health record. The COVID-19 pandemic provided an additional application for the company’s analytics capabilities. In 2020, Sophia Genetics released a solution focused on predicting the evolution of SARS-CoV-2 disease. Its later research agenda continued to move beyond conventional sequence interpretation. In 2022, the company began developing an approach for detecting extrachromosomal DNA with Boundless Bio and committed to a collaboration with Memorial Sloan Kettering Cancer Center on predictive tumor analysis and clinical decision support. Sophia Genetics became a public company through an initial public offering in July 2021. The offering was backed by J.P. Morgan, Morgan Stanley, and Credit Suisse, although the available reference material does not provide a ticker or financial terms. In 2023, Sophia Genetics partnered with QIAGEN on somatic variant detection and joined AstraZeneca and Memorial Sloan Kettering in an effort to extend access to MSK blood and tumor sequencing tests through its platform. In 2024, it collaborated with NVIDIA and Microsoft on a whole-genome sequencing application. Across its history, Sophia Genetics has remained focused on professional users and institutional workflows. Its business combines software, bioinformatics, clinical interpretation, and partnerships with technology and life-science organizations. The company’s platform strategy seeks to make complex genomic, radiomic, and multimodal datasets more usable in diagnosis, treatment selection, research, and clinical decision support.
- 2024
Whole-genome sequencing collaboration
[1]Sophia Genetics collaborated with NVIDIA and Microsoft on a whole-genome sequencing application.
- 2023
QIAGEN, AstraZeneca, and MSK collaborations
[1]The company announced work with QIAGEN on somatic variant detection and with AstraZeneca and Memorial Sloan Kettering on wider access to sequencing tests.
- 2021
Initial public offering
[1]Sophia Genetics completed an IPO in July 2021.
- 2020
SARS-CoV-2 analysis solution released
[1]The company released a data-analysis solution focused on predicting SARS-CoV-2 disease evolution.
- 2018
French R&D and United States expansion
[1]Sophia Genetics established a French R&D center, acquired Interactive Biosoftware, and opened its Boston headquarters.
- 2016
Illumina co-marketing agreement
[1]The company entered an agreement with Illumina to promote next-generation DNA sequencing adoption.
- 2014
SOPHiA DDM Platform introduced
[1]Sophia Genetics launched its data-driven medicine platform for genomic analysis and clinical interpretation.
- 2011
Company founded at EPFL
[1]Jurgi Camblong, Pierre Hutter, and Lars Steinmetz co-founded Sophia Genetics as a start-up associated with the École Polytechnique Fédérale de Lausanne.
Products and positioning
An enterprise data-driven medicine platform that connects genomic, radiomic, and clinical information for hospitals, laboratories, biopharma organizations, and researchers.
Genomic data analysis and clinical interpretation · 2014
SOPHiA DDM Platform
Sophia Genetics’ principal data-driven medicine platform is designed to process and interpret genomic information generated by next-generation sequencing. It applies computational analytics and artificial-intelligence methods to support clinical and research workflows. The platform has been used across oncology, hereditary cancer, metabolic disease, pediatrics, cardiology, and rare-disease research, and can analyze data from blood, urine, cerebrospinal fluid, and other liquid samples.
Radiomic and multimodal clinical analytics
SOPHiA DDM radiomic and multimodal analysis
This area of the company’s platform strategy extends analysis beyond genomic sequence data to radiomic and other multimodal information. The intended use is to combine molecular, imaging, and clinical records to support disease characterization, treatment analysis, predictive tumor work, and clinical decision support. The available reference material does not identify a separate commercial product name or launch date for each application.
Infectious-disease analytics · 2020
SARS-CoV-2 disease-evolution analysis solution
Released in 2020, this solution applied the company’s data-analysis capabilities to SARS-CoV-2 and was focused on predicting disease evolution. The available material describes it as a data-analysis solution rather than as a standalone diagnostic test.
Whole-genome sequencing software · 2024
Whole-genome sequencing application
In collaboration with NVIDIA and Microsoft, Sophia Genetics announced a whole-genome sequencing application in 2024. The application is part of the company’s effort to provide scalable computational analysis for comprehensive genomic datasets. Detailed product specifications and commercial availability are not established in the supplied material.
Brand decisions
2024
Whole-genome sequencing application collaborationProduct launchBackground
Whole-genome sequencing creates substantial computational and interpretation requirements for clinical and research users.
Action taken
Sophia Genetics collaborated with NVIDIA and Microsoft to launch a whole-genome sequencing application.
Aftermath
The collaboration extended the company’s platform strategy toward comprehensive genome analysis using cloud and accelerated-computing infrastructure.
2022
Development of extrachromosomal DNA detectionStrategyBackground
Extrachromosomal DNA can be relevant to cancer biology and tumor behavior, creating an opportunity for specialized genomic analysis.
Action taken
Sophia Genetics began developing a detection method in collaboration with Boundless Bio.
Aftermath
The work expanded the company’s research focus toward tumor biology and advanced genomic biomarkers.
2021
Initial public offeringOtherBackground
Sophia Genetics pursued access to public equity markets as it expanded its healthcare and life-science software business.
Action taken
The company completed an initial public offering in July 2021, with J.P. Morgan, Morgan Stanley, and Credit Suisse among the supporting banks.
Aftermath
Sophia Genetics became a publicly listed company. The supplied material does not provide the offering valuation, proceeds, or ticker.
2018
Acquisition of Interactive BiosoftwareM&ABackground
Sophia Genetics was expanding its genomic-analysis capabilities and international operating footprint.
Action taken
The company acquired Interactive Biosoftware, a France-based molecular biology and genetic-analytics software developer.
Aftermath
The acquisition supported the establishment of a French research and development presence and broadened Sophia Genetics’ software capabilities.
2018
Expansion into the United States and FranceStrategyBackground
Sophia Genetics sought to develop a broader international presence in healthcare software and genomic analytics.
Action taken
The company opened a United States headquarters in Boston and established its first research and development center in France.
Aftermath
The expansion gave the company operating and development bases in Switzerland, France, and the United States.
Recent events
Dasa expands partnership with SOPHiA GENETICS[2]
Reported:
Dasa expanded its partnership with SOPHiA GENETICS to offer a decentralized homologous recombination deficiency (HRD) analytics solution in Latin America.
SOPHiA GENETICS appoints Ross Muken as CFO[3]
Reported:
SOPHiA GENETICS appointed Ross Muken as its chief financial officer.
SOPHiA GENETICS nominates Kathy L. Hibbs to its board[4]
Reported:
SOPHiA GENETICS announced that Kathy L. Hibbs was nominated to its Board of Directors and Audit Committee.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/sophia-genetics · Editorial policy · How profiles are compiled